RT Journal Article
SR Electronic
T1 Genotype-phenotype correlations in <em>SCN8A</em>-related disorders reveal prognostic and therapeutic implications
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.22.21253711
DO 10.1101/2021.03.22.21253711
A1 Johannesen, Katrine M
A1 Liu, Yuanyuan
A1 Gjerulfsen, Cathrine E
A1 Koko, Mahmoud
A1 Sonnenberg, Lukas
A1 Schubert, Julian
A1 Fenger, Christina D
A1 Eltokhi, Ahmed
A1 Rannap, Maert
A1 Koch, Nils A.
A1 Lauxmann, Stephan
A1 Krüger, Johanna
A1 Kegele, Josua
A1 Canafoglia, Laura
A1 Franceschetti, Silvana
A1 Mayer, Thomas
A1 Rebstock, Johannes
A1 Zacher, Pia
A1 Ruf, Susanne
A1 Alber, Michael
A1 Sterbova, Katalin
A1 Lassuthová, Petra
A1 Vlckova, Marketa
A1 Lemke, Johannes R
A1 Krey, Ilona
A1 Heine, Constanze
A1 Wieczorek, Dagmar
A1 Kroell-Seger, Judith
A1 Lund, Caroline
A1 Klein, Karl Martin
A1 Au, PY Billie
A1 Rho, Jong M
A1 Ho, Alice W
A1 Masnada, Silvia
A1 Veggiotti, Pierangelo
A1 Giordano, Lucio
A1 Accorsi, Patrizia
A1 Hoei-Hansen, Christina E
A1 Striano, Pasquale
A1 Zara, Federico
A1 Verhelst, Helene
A1 S.Verhoeven, Judith
A1 van der Zwaag, Bert
A1 Harder, Aster V. E.
A1 Brilstra, Eva
A1 Pendziwiat, Manuela
A1 Lebon, Sebastian
A1 Vaccarezza, Maria
A1 Le, Ngoc Minh
A1 Christensen, Jakob
A1 Schmidt-Petersen, Mette U
A1 Grønborg, Sabine
A1 Scherer, Stephen W
A1 Howe, Jennifer
A1 Fazeli, Walid
A1 Howell, Katherine B
A1 Leventer, Richard
A1 Stutterd, Chloe
A1 Walsh, Sonja
A1 Gerard, Marion
A1 Gerard, Bénédicte
A1 Matricardi, Sara
A1 Bonardi, Claudia M
A1 Sartori, Stefano
A1 Berger, Andrea
A1 Hoffman-Zacharska, Dorota
A1 Mastrangelo, Massimo
A1 Darra, Francesca
A1 Vøllo, Arve
A1 Motazacker, M Mahdi
A1 Lakeman, Phillis
A1 Nizon, Mathilde
A1 Betzler, Cornelia
A1 Altuzarra, Cecilia
A1 Caume, Roseline
A1 Roubertie, Agathe
A1 Gélisse, Philippe
A1 Marini, Carla
A1 Guerrini, Renzo
A1 Bilan, Frederic
A1 Tibussek, Daniel
A1 Koch-Hogrebe, Margarete
A1 Perry, M Scott
A1 Ichikawa, Shoji
A1 Dadali, Elena
A1 Sharkov, Artem
A1 Mishina, Irina
A1 Abramov, Mikhail
A1 Kanivets, Ilya
A1 Korostelev, Sergey
A1 Kutsev, Sergey
A1 Wain, Karen E
A1 Eisenhauer, Nancy
A1 Wagner, Monisa
A1 Savatt, Juliann M
A1 Müller-Schlüter, Karen
A1 Bassan, Haim
A1 Borovikov, Artem
A1 Nassogne, Marie-Cecile
A1 Destrée, Anne
A1 Schoonjans, An-Sofie
A1 Meuwissen, Marije
A1 Buzatu, Marga
A1 Jansen, Anna
A1 Scalais, Emmanuel
A1 Srivastava, Siddharth
A1 Tan, Wen-Hann
A1 Olson, Heather E
A1 Loddenkemper, Tobias
A1 Poduri, Annapurna
A1 Helbig, Katherine L
A1 Helbig, Ingo
A1 Fitzgerald, Mark P
A1 Goldberg, Ethan M
A1 Roser, Timo
A1 Borggraefe, Ingo
A1 Brünger, Tobias
A1 May, Patrick
A1 Lal, Dennis
A1 Lederer, Damien
A1 Rubboli, Guido
A1 Lesca, Gaetan
A1 Hedrich, Ulrike BS
A1 Benda, Jan
A1 Gardella, Elena
A1 Lerche, Holger
A1 Møller, Rikke S
YR 2021
UL http://medrxiv.org/content/early/2021/03/26/2021.03.22.21253711.abstract
AB We report detailed functional analyses and genotype-phenotype correlations in 433 individuals carrying disease-causing variants in SCN8A, encoding the voltage-gated Na+ channel NaV1.6. Five different clinical subgroups could be identified: 1) Benign familial infantile epilepsy (BFIE) (n=17, normal cognition, treatable seizures), 2) intermediate epilepsy (n=36, mild ID, partially pharmacoresponsive), 3) developmental and epileptic encephalopathy (DEE, n=191, severe ID, majority pharmacoresistant), 4) generalized epilepsy (n=21, mild to moderate ID, frequently with absence seizures), and 5) affected individuals without epilepsy (n=25, mild to moderate ID). Groups 1-3 presented with early-onset (median: four months) focal or multifocal seizures and epileptic discharges, whereas the onset of seizures in group 4 was later (median: 39 months) with generalized epileptic discharges. The epilepsy was not classifiable in 143 individuals. We performed functional studies expressing missense variants in ND7/23 neuroblastoma cells and primary neuronal cultures using recombinant tetrodotoxin insensitive human NaV1.6 channels and whole-cell patch clamping. Two variants causing DEE showed a strong gain-of-function (GOF, hyperpolarising shift of steady-state activation, strongly increased neuronal firing rate), and one variant causing BFIE or intermediate epilepsy showed a mild GOF (defective fast inactivation, less increased firing). In contrast, all three variants causing generalized epilepsy induced a loss-of-function (LOF, reduced current amplitudes, depolarising shift of steady-state activation, reduced neuronal firing). Including previous studies, functional effects were known for 165 individuals. All 133 individuals carrying GOF variants had either focal (76, groups 1-3), or unclassifiable epilepsy (37), whereas 32 with LOF variants had either generalized (14), no (11) or unclassifiable (5) epilepsy; only two had DEE. Computational modeling in the GOF group revealed a significant correlation between the severity of the electrophysiological and clinical phenotypes. GOF variant carriers responded significantly better to sodium channel blockers (SCBs) than to other anti-seizure medications, and the same applied for all individuals of groups 1-3.In conclusion, our data reveal clear genotype-phenotype correlations between age at seizure onset, type of epilepsy and gain- or loss-of-function effects of SCN8A variants. Generalized epilepsy with absence seizures is the main epilepsy phenotype of LOF variant carriers and the extent of the electrophysiological dysfunction of the GOF variants is a main determinant of the severity of the clinical phenotype in focal epilepsies. Our pharmacological data indicate that SCBs present a therapeutic treatment option in early onset SCN8A-related focal epilepsy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the German research foundation and the Fonds Nationale de la Recherche in Luxembourg (Research Unit FOR-2715, DFG grants Le1030/15-1 and /16-1 to HL, He8155/1-1 to UBSH, He5415/7-1 to IH, FNR grant INTER/DFG/17/11583046 to PM), the German Federal Ministry for Education and Research (BMBF, Treat-ION, 01GM1907A to HL, DL and PM), the foundation no epilep (to HL to partially support LS), the Medical Faculty of the University of Tuebingen (the Fortuene program 2430-00 to SL). KS, PL, MV were funded by grant: MH CR AZV NU20-04-00279. Epi25 was supported by the National Human Genome Research Institute (NHGRI) grants UM1 HG008895 and 5U01HG009088-02, and the Stanley Center for Psychiatric Research at the Broad Institute. SI was employed by and received a salary from Ambry Genetics. SS hold the GlaxoSmithKline Endowed Chair in Genome Sciences at the Hospital for Sick Children and University of Toronto. P.S. has received speaker fees and participated at advisory boards for Biomarin, Zogenyx, GW Pharmaceuticals, and has received research funding by ENECTA BV, GW Pharmaceuticals, Kolfarma Srl., Eisai. EM was funded by grant: NIH NINDS K08 NS097633 and Foerderer Award for Excellence from The Childrens Hospital of Philadelphia Research Institute. PV received a speaker fee from Nutricia GmbH, Dr. Schar AG / SPA, Eisai. Nestle, Pediatrica. FZ and PS developed this work within the framework of the DINOGMI Department of Excellence of MIUR 2018-2022 (legge 232 del 2016). IH was also supported by The Hartwell Foundation through an Individual Biomedical Research Award. This work was also supported by the National Institute for Neurological Disorders and Stroke (K02 NS112600), including support through the Center Without Walls on ion channel function in epilepsy (Channelopathy-associated Research Center, U54 NS108874), the Eunice Kennedy Shriver National Institute of Child Health and Human Development through the Intellectual and Developmental Disabilities Research Center (IDDRC) at Childrens Hospital of Philadelphia and the University of Pennsylvania (U54 HD086984), and by intramural funds of the Childrens Hospital of Philadelphia through the Epilepsy NeuroGenetics Initiative (ENGIN). Research reported in this publication was also supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number UL1TR001878. This project was also supported in part by the Institute for Translational Medicine and Therapeutics (ITMAT) Transdisciplinary Program in Translational Medicine and Therapeutics at the Perelman School of Medicine of the University of Pennsylvania.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the local ethical committees or followed other local guidelines as following: The ethics committee of Region Sjælland, Denmark: SJ-91 Ethics Committee Antwerp University Hospital, Drie Eikenstraat 655, 2650 Edegem, Belgium Ethical Committees of the Medical Faculty of the University of Munich Ethics Committee at the Research Centre for Medical Genetics, Moscow, Russian Republic Ethics committee of the University of Leipzig (ethical approval 224/16-ek, 402/16-ek)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be made available upon request